Table 2 |
||||
|
Prognostic signatures |
||||
| Signature symbol |
Reference |
Associated variables in gene selection procedure |
Number of genes |
|
|
|
||||
| Original probes |
Mapped to geneID |
|||
|
|
||||
| ONC-16 |
[42] |
Biological knowledge; refined by patient outcome |
16 |
16 |
| NKI-70 |
[19] |
Patient outcome |
70 |
52 |
| EMC-76 |
[21] |
Patient outcome, stratified by estrogen receptor status |
60 + 16 |
48 + 12 |
| NCH-70 |
[12] |
Patient outcome |
70 |
69 |
| CON-52 |
[43] |
Patient outcome, consensus |
52 |
50 |
| p53-32 |
[11] |
p53 mutation |
32 |
19 |
| CSR |
[24] |
Fibroblast core serum response |
512 |
457 |
| GGI-128 |
[18] |
Histological grade |
128 |
98 |
| CCYC |
[44] |
Periodic expression in cell cycle progression |
NA |
126 |
|
|
||||
|
NA, not applicable. |
||||
|
Wirapati et al. Breast Cancer Research 2008 10:R65 doi:10.1186/bcr2124 |
||||